BENTLEY PHARMACEUTICALS INC Form 8-K May 08, 2008

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 8, 2008

Date of Report (Date of Earliest Event Reported) BENTLEY PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or Other Jurisdiction of Incorporation)

1-10581 59-1513162

(Commission File Number)

(I.R.S. Employer Identification No.)

Bentley Park
2 Holland Way
Exeter, New Hampshire

Address of Principal Executive Office

03833

(Zip Code)

(Address of Principal Executive Offices)

(603) 658-6100

(Registrant s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Item 2.02. Results of Operations and Financial Condition.

Item 9.01. Financial Statements and Exhibits.

SIGNATURES

EXHIBIT INDEX

Ex-99.1 Earnings press release for the three months ended March 31, 2008

Table of Contents

BENTLEY PHARMACEUTICALS, INC.

Item 2.02. Results of Operations and Financial Condition.

On May 8, 2008, Bentley Pharmaceuticals, Inc. issued a press release announcing financial results for the three months ended March 31, 2008. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

99.1 Earnings press release for the three months ended March 31, 2008 dated May 8, 2008.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 8, 2008 By: /s/ Richard P. Lindsay

Richard P. Lindsay

Vice President and Chief Financial

Officer

Table of Contents

BENTLEY PHARMACEUTICALS, INC. EXHIBIT INDEX

Exhibit

Number Description of Exhibit

Earnings press release for the three months ended March 31, 2008 dated May 8, 2008.